Results 141 to 150 of about 1,389,538 (204)
Mignot and Yanagisawa win Lasker prize for discovery of the role of orexins in wake, sleep, and narcolepsy. [PDF]
Saper CB.
europepmc +1 more source
To sleep and dream: Unraveling narcolepsy. [PDF]
Friedman JM.
europepmc +1 more source
Emerging pharmacological targets in migraine therapy: CGRP and beyond. [PDF]
Atraszkiewicz D, Dahiya D.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Orexin Receptor Antagonists and Insomnia
Current Psychiatry Reports, 2022We review recent evidence on the use of orexin receptor antagonists (ORAs) for treating insomnia. We evaluate studies on five dual ORAs and one selective ORA.Research on suvorexant in recent years gradually focus on comorbid insomnia, while lemborexant and daridorexant were still being validated in primary insomnia.
Zhouqing Chen, Tao Xue
exaly +3 more sources
Antagonists of the Orexin Receptors
Expert Opinion on Therapeutic Patents, 2006Orexin-A and orexin-B are neuropeptides that are produced by neurons in the lateral hypothalamus. These neuropeptides bind and activate two closely related G-protein-coupled receptors, orexin-1 and orexin-2, and are involved in a variety of biological functions, including feeding, sleep–wake cycle, regulation of gastric acid secretion and reward ...
Jiaqiang Cai
exaly +2 more sources
Bioorganic and Medicinal Chemistry Letters, 2017
In an ongoing effort to explore the use of orexin receptor antagonists for the treatment of insomnia, dual orexin receptor antagonists (DORAs) were structurally modified, resulting in compounds selective for the OX2R subtype and culminating in the discovery of 23, a highly potent, OX2R-selective molecule that exhibited a promising in vivo profile ...
Christopher Winrow +2 more
exaly +3 more sources
In an ongoing effort to explore the use of orexin receptor antagonists for the treatment of insomnia, dual orexin receptor antagonists (DORAs) were structurally modified, resulting in compounds selective for the OX2R subtype and culminating in the discovery of 23, a highly potent, OX2R-selective molecule that exhibited a promising in vivo profile ...
Christopher Winrow +2 more
exaly +3 more sources
Selective orexin receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2013The orexin, or hypocretin, neuropeptides (orexin-A and orexin-B) are produced on neurons in the hypothalamus which project to key areas of the brain that control sleep-wake states, modulation of food intake, panic, anxiety, emotion, reward and addictive behaviors.
Terry P, Lebold +2 more
openaire +2 more sources
Pharmaceutical Patent Analyst, 2012
The orexin neuropeptides bind to two G protein-coupled receptors, orexin-1 and -2. Small-molecule antagonism of the receptors has potential therapeutic utility in a number of areas, most notably insomnia, for which the most advanced dual orexin receptor antagonist has now completed clinical trials.
openaire +2 more sources
The orexin neuropeptides bind to two G protein-coupled receptors, orexin-1 and -2. Small-molecule antagonism of the receptors has potential therapeutic utility in a number of areas, most notably insomnia, for which the most advanced dual orexin receptor antagonist has now completed clinical trials.
openaire +2 more sources

